Cervical Cancer

Almost all cervical cancers can be attributed to four HPV types: 16, 18, 45 and 31.  In 2003, the American Cancer Society estimated that approximately 12,200 women in the U.S. would be diagnosed with invasive cervical cancer and that about 4,100 patients would die from the disease (*) .  Globally, an estimated 400,000 new cases of cervical cancer are identified each year. Although death rates from cervical cancer have declined in developed countries, invasive cervical cancer continues to be associated with extreme morbidity in the rest of the world.  Because of the mortality rates, the World Health Organization has called cervical cancer the second most important cancer threat in women after breast cancer.

There are no FDA-approved drug therapies. Patients with cancer are typically treated with surgery and radiation.  If the cancer spreads, chemotherapy can be used to treat the cancer in other areas of the body.

Serious HPV-related diseases

• Recurrent Repiratory Papillomatosis (RRP)
• Genital warts
• Cervical intraepithelial neoplasia (CIN) and failures of LEEP
• HPV Infection in Immunocompromised Patients
• Head and Neck Cancer
• Cervical cancer
• Anal intraepithelial neoplasia (AIN)

The Nventa Solution - HspE7

(*) Sources: World Health Organization; National Institute of Health, Center for Disease Control; National Cancer Institute; National Institute of Allergy and Infectious Diseases.